Product Overview
[Drug Name]
Generic Name: Famotidine Tablets
Trade Name: BiDi Famotidine Tablets 20mg*24 Tablets
Pinyin Full Code: BiDi FaMoTiDingPian 20mg*24 Tablets
[Main Ingredients]
Each tablet contains 20mg of the main ingredient, famotidine. Excipients are lactose, hydroxypropylcellulose, tapioca starch, sodium starch glycolate, and magnesium stearate. Chemical Name: 3-[[[2-[(diaminomethylene)-4-thiazolyl]methyl]thio]-N-sulfamoylpropionamidine Molecular Formula: C8H15N7O2S3 Molecular Weight: 337.45
[Properties]
This product is a white tablet.
[Indications/Main Functions]
Used to relieve stomach pain, heartburn, and acid reflux caused by excessive gastric acid.
[Specifications]
20mg*24 tablets
[Dosage and Administration]
Oral. Adults: Take one tablet twice daily. Do not exceed two tablets in 24 hours.
[Adverse Reactions]
A small number of patients may experience dry mouth, dizziness, insomnia, constipation, diarrhea, rash, facial flushing, and leukopenia. Mild transient elevations of transaminases may occur occasionally.
[Contraindications]
1. Contraindicated in patients with severe renal insufficiency.
2. Contraindicated in pregnant and lactating women.
[Precautions]
1. Do not use this product continuously for more than 7 days. Consult a physician or pharmacist if symptoms persist.
2. Contraindicated in patients with a history of allergic reactions, severe renal insufficiency, or pregnant or lactating women.
3. This product should only be used by children under the guidance of a physician.
4. Use with caution in patients with hepatic or renal impairment and in infants and young children.
5. In case of overdose or serious adverse reactions, seek medical attention immediately.
6. Do not use if the product's properties change.
7. Children must be supervised by an adult. 8. Keep this medicine out of reach of children.
9. Use only after gastric cancer has been ruled out.
[Drug Interactions]
This product does not interact with hepatic cytochrome P450 enzymes and therefore does not affect the metabolism of drugs such as theophylline, phenytoin, warfarin, and diazepam, nor does it affect the body distribution of drugs such as procainamide. However, probenecid may inhibit the renal tubular excretion of famotidine.
[Pediatric Use]
Use with caution in infants and young children.
[Elderly Use]
The effect is unknown.
[Pregnant and Lactating Women Use]
This product is contraindicated in pregnant and lactating women.
[Overdose]
The effect is unknown.
[Pharmacology and Toxicology]
This product is a histamine H2 receptor blocker. It has a significant inhibitory effect on gastric acid secretion and may also inhibit the secretion of pepsin, showing some protective effects against experimental ulcers in animals. The onset of action is approximately one hour after administration, and the effect lasts for more than 12 hours.
[Pharmacokinetics]
Following oral administration, 14C-famotidine is rapidly absorbed in healthy volunteers in China, reaching peak blood concentrations in approximately 2 hours and a half-life of approximately 3 hours. Literature reports indicate that after oral or intravenous administration of 14C-famotidine to rats, radioactivity is elevated in the digestive tract, liver, kidneys, submandibular gland, and pancreas. 80% of the unchanged substance is excreted in the urine, and the inhibitory effect on hepatic enzymes is minimal.
[Storage]
Store in a sealed container away from light.
[Packaging]
Aluminum-plastic packaging, 24 tablets per box.
[Expiry Period]
24 months
[Approval Number]
National Medicine Standard H44021617
[Manufacturer]
Guangdong BIDI Pharmaceutical Co., Ltd.
